<DOC>
	<DOC>NCT03031119</DOC>
	<brief_summary>Part A will investigate the safety, tolerability, PK and PD of PF-06835919 administered for 14 days in a multiple ascending dose design. Part B will assess the effect of PF-06835919 co-administration at low and high doses on the PK of atorvastatin in a single cohort.</brief_summary>
	<brief_title>Multiple Ascending Dose and DDI Study</brief_title>
	<detailed_description />
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Healthy male and females (nonchildbearing potential) 18 to 55 years old Body Mass Index 17.5 to 30.5 Known hereditary fructose intolerance or fructose malabsorption disorder (Part A) Statin intolerance (Part B) Unable to consume high fructose syrupcontaining beverage with each meal while in the unit (Part A)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>nonalcoholic steatohepatitis</keyword>
</DOC>